Invasive and non-invasive neuromodulation in movement disorders
- Submission status
- Open
- Submission deadline
Invasive neuromodulation therapies in movement disorders that target specific brain regions have paved the way for modulation of specific underlying networks. Deep Brain Stimulation (DBS) is a well-established therapy for movement disorders - namely Parkinson disease, tremor, and dystonia - whereas non-invasive stimulation such as focused ultrasound stimulation (FUS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (TDCS) are in experimental or preclinical stages.
There is consensus that movement disorders are caused by dysfunction of neuronal circuits, which makes this a key target for patient treatment. At present, treating these disorders is primarily focused on phenotypes specific to Parkinson’s disease (i.e. motor symptoms, for example: dyskinesia, akinesia, tremor etc). However, non-motor symptoms also jeopardize the quality of life for individuals with these disorders, and should also be considered in treatment options. Treating the entire network dysfunction may therefore represent the best strategy to overcome both motor and non-motor symptoms.
This Collection will showcase developments in invasive and non-invasive neuromodulation therapies that will advance the field towards this aim for holistic treatment. We particularly welcome submissions on topics such as:
- Developments in established invasive neuromodulation therapies (For ex: deep brain stimulation) for treating movement disorders patients specially Parkinson’s disease, tremor and dystonia.
- Experimental and preclinical non-invasive stimulation therapies (FUS, TMS, TDCS, TACS) for treating movement disorders patients specially Parkinson’s disease, tremor, and dystonia.
- Emerging neuromodulation (e.g. opto- or pharmaco- genetics, ultrasonic and neurofeedback) technologies and future perspective for treating movement disorders.
- Electrophysiological approaches that foster and improve neuromodulation therapies.
- Advanced multimodal neuroimaging techniques to derive underlying neuronal networks involved in movement disorders.
- Translational approaches for improving invasive neuromodulation therapies for movement disorders.
Editors
-
Muthuraman Muthuraman, PhD
Neural Engineering with Signal Analytics and Artificial Intelligence (NESA-AI), Universitätsklinikum Würzburg Department of Neurology, Würzburg, Germany
-
Aparna Wagle Shukla, MD
Norman Fixel Institute for Neurological Diseases, University of Florida, FL, USA
All articles have undergone npj Parkinson's Disease's standard peer review process and have been subject to all the journal’s standard policies. This includes the journal’s policy on competing interests. The Editors declare no competing interests with the submissions which they have handled through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.
If accepted for publication, an article processing charge applies (with standard waiver policy). If your institution or country has an open access agreement with Springer Nature, you may publish your article OA at no cost or in some cases with the costs partially funded (see details here).
All Collections are open for submissions from all authors – and not by invitation only – on the condition that the manuscripts fall within the scope of the Collection and of npj Parkinson's Disease more generally. Manuscripts submitted to an open Collection may be considered unsuitable for inclusion, particularly if they fall outside the scope of the Collection. In such cases, the authors will be notified by the editorial office and their manuscript can be considered as a regular npj Parkinson's Disease submission.
npj Parkinson's Disease’s in-house editors reserve the right to assume responsibility for the management of a Collection at any stage.
